Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer

Annals of Oncology

Volumn 20, Issue 6, 2009, Pages 1020-1025

  Kioulafa, M ^a   Kaklamanis, L ^b   Stathopoulos, E ^c   Mavroudis, D ^c   Georgoulias, V ^c   Lianidou, E S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

DNA methylation; Early breast cancer; Epigenetic markers; KLK10; Methylation specific PCR; Prognostic biomarker

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GENOMIC DNA; KALLIKREIN; KALLIKREIN 10; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; DNA METHYLATION; EARLY CANCER; EXON; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; SURVIVAL TIME;

BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; HUMANS; KALLIKREINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 66149102406     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn733     Document Type: Article

References (19)

1. Gralow J, Ozols RF, Bajorin DF et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26: 313-325.
2. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007; 447: 425.
3. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
4. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116.
5. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
6. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890.
7. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine proteaselike gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996; 56: 3371-3379.
8. Yousef GM, Yacoob GM, Polymeris ME et al. Kallikrein gene downregulation in breast cancer. Br J Cancer 2004; 90: 167-172.
9. Goyal J, Smith KM, Cowan JM et al. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998; 58: 4782-4786.
10. Li B, Goyal J, Dhar S et al. CpG methylation as a basis for breast tumorspecific loss of NES1/kallikrein 10 expression. Cancer Res 2001; 61: 8014-8021.
11. Sidiropoulos M, Pampalakis G, Sotiropoulou G et al. Downregulation of human kallikrein 10 (hK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol 2005; 26: 324-336.
12. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al. The normal epithelial cellspecific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 2004; 18: 362-365.
13. Huang W, Zhong J, Wu L et al. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett 2007; 251: 78-85.
14. Dhar S, Bhargava R, Yunes M et al. Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res 2001; 7: 3393-3398.
15. Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
16. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
17. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001; 61: 3105-3109.
18. Agathanggelou A, Honorio S, Macartney DP et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001; 20: 1509-1518.
19. Fackler MJ, McVeigh M, Evron E et al. DNA methylation of RASSF1A, HIN-1, RAR-β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107: 970-975.